Volitionrx Ltd
VNRX- Exchange
- NYSE
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000093314
No open-market purchases or sales by Volitionrx Ltd insiders were filed in the last 90 days; 24 institutions reported holding it in 13F filings for Q2 2026, worth $2.61M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −7 vs. previous quarter
- 24
- 13F valueReported value at the end of Q2 2026
- $2.61M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding VNRX, Q2 2026
No superinvestor reported holding VNRX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Volitionrx Ltd insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 17, 2025 (view filing)1:12 PM ET | Nov 17 | Same day | Reynolds Cameron JohnPresident and CEO | PPurchase | +20.0K | $0.35 | +$7.00K | +0.8%2.55M after | |
| Oct 15, 2025 (view filing)4:05 PM ET | Oct 14 | 1 day | Reynolds Cameron JohnPresident and CEO | PPurchase | +110.0K | $0.51 | +$56.1K | +4.5%2.53M after | |
| Oct 15, 2025 (view filing)4:05 PM ET | Oct 14 | 1 day | Reynolds Cameron JohnPresident and CEO | PPurchase | +110.0K | $0.01 | +$1.10K | –110.0K after | Derivative |
| Oct 15, 2025 (view filing)4:05 PM ET | Oct 14 | 1 day | Innes Guy ArchibaldDirector | PPurchase | +96.2K | $0.51 | +$49.0K | +9.9%1.06M after | |
| Oct 15, 2025 (view filing)4:05 PM ET | Oct 14 | 1 day | Innes Guy ArchibaldDirector | PPurchase | +96.2K | $0.01 | +$961.53 | –96.2K after | Derivative |
| Oct 15, 2025 (view filing)4:05 PM ET | Oct 14 | 1 day | Still Timothy IDirector | PPurchase | +48.1K | $0.51 | +$24.5K | +3.2%1.54M after | |
| Oct 15, 2025 (view filing)4:05 PM ET | Oct 14 | 1 day | Still Timothy IDirector | PPurchase | +48.1K | $0.01 | +$480.76 | –48.1K after | Derivative |
| Sep 15, 2025 (view filing) | Sep 12 | 3 days | Reynolds Cameron JohnPresident and CEO | PPurchase | +15.0K | $0.66 | +$9.90K | +0.6%2.62M after | |
| Aug 6, 2025 (view filing) | Aug 5 | 1 day | Innes Guy ArchibaldDirector | PPurchase | +78.1K | $0.64 | +$50.0K | +8.8%966.8K after | |
| Aug 6, 2025 (view filing) | Aug 5 | 1 day | Reynolds Cameron JohnPresident and CEO | PPurchase | +78.1K | $0.64 | +$50.0K | +3.1%2.61M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Volitionrx Ltd at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Lagoda Investment Management, L.P. | 1,455,950 | $1.97M | 1.08% | −14,693,050−91.0% | Reduced |
| Luminus Management LLC | 156,897 | $211.8K | 0.14% | −838,103−84.2% | Reduced |
| Geode Capital Management, LLC | 55,537 | $75.0K | 0.00% | −1,174,546−95.5% | Reduced |
| Vanguard Capital Management LLC | 50,684 | $68.4K | 0.00% | −962,989−95.0% | Reduced |
| Wealthspire Advisors, LLC | 45,000 | $60.8K | 0.00% | −175,000−79.5% | Reduced |
| State Street Corp | 33,995 | $45.9K | 0.00% | −645,943−95.0% | Reduced |
| XTX Topco Ltd | 25,381 | $34.3K | 0.00% | −20,679−44.9% | Reduced |
| Vanguard Fiduciary Trust Co | 25,133 | $33.9K | 0.00% | −477,524−95.0% | Reduced |
| BlackRock, Inc. | 22,308 | $30.1K | 0.00% | −423,879−95.0% | Reduced |
| Northern Trust Corp | 12,978 | $17.5K | 0.00% | −246,615−95.0% | Reduced |